The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C. Do not freeze.
Application:
ELISA Detection1-4, ELISPOT Detection5,6
Recommended Usage:
Each lot of this antibody is quality control tested by ELISA assay. For use as an ELISA detection antibody, a concentration range of 0.25-1.0 μg/ml is recommended. To obtain a linear standard curve, serial dilutions of human IL-5 protein ranging from 250 to 1 pg/ml are recommended for each ELISA plate when paired with TRFK5 (Cat. # 504302). To obtain a linear standard curve, serial dilutions of human IL-5 protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate when paired with JES1-39D10 (Cat. # 500902).
For use as an ELISPOT detection antibody, a concentration range of 1-4 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
ELISA1-4 or ELISPOT5,6 Detection: The biotinylated JES1-5A10 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES1-39D10 (Cat. No. 500902/500907) or TRFK5 (Cat. No. 504302/504308) antibody as the capture antibody.
Biotin-F(ab') (Cat. No. 501005) is recommended for ELISA analysis of human serum and plasma samples, to prevent non-specific binding of interfering substances such as rheumatoid factor and heterophilic antibodies. Each lot of this antibody is quality control tested by ELISA assay. Neutralization1-3: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm sterile-filtered) is recommended for neutralization of human IL-5 bioactivity (Cat. No. 501004).
Note: For testing human IL-5 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430401 to 430406) are specially developed and recommended.
Application References:
1. Abrams, J., et al., 1992.. Immunol. Rev. 127: 5. 2. Abrams, J., et al., 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker, New York. p.133. 3. Butterfield, J., et al., 1991. Blood 79: 688. 4. Limaye, A., et al., 1991. J. Clin. Inv. 88: 1418. 5. Klinman, D., et al., 1994. Curr. Prot. Immunol.. John Wiley and Sons, New York. Unit 6.19. 6. Mahanty, S., et al., 1992. J. Immunol. 148: 3567.
Description:
IL-5 is a homodimeric, disulphide-linked protein produced by T-cells. Monomeric human IL-5 is a 126 amino acid protein with a reported molecular weight of 26 kD for the homodimeric protein. Mouse and human IL-5 are approximately 70% identical. IL-5 has been shown to promote the growth of immature hematopoietic BFU-E progenitors, stimulate the activation and differentiation of eosinophils, and promote the generation of cytotoxic lymphocytes. The JES1-5A10 antibody can neutralize the bioactivity of natural or recombinant IL-5.
Other Names:
Interleukin-5, Eosinophil differentiation factor (EDF), Eosinophil colony stimulating factor (Eo-CSF), B cell growth factor-2 (BCGF-2), B cell differentiation factor for IgM (BCDF-m), IgA enhancing factor (IgA-EF), T cell replacing factor-1 (TRF-1)
Structure:
Cytokine; dimer; 45 kD (Mammalian)
Regulation:
Upregulated by IL-2, platelet activating factor; downregulated by TGF-β
Cellular Sources:
Mast cells, T cells, bone marrow stromal cells
Cellular Targets:
Eosinophils
Receptors:
Heterodimer IL-5Rα (CD125); β-subunit (CDw131) in common with IL-3R, GM-CSFR
Bioactivity/Activities:
Growth/differentiation of eosinophils; proliferation/cell activation/differentiation of eosinophilic granulocytes
Antigen References:
1. Fitzgerald, K., et al., Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Takatsu, K., et al., 1988. Immunol. Rev. 102:107. 3. Takatsu, K. 1992. Curr. Opin. Immunol. 4:299. 4. Takatsu, K. 1991. Microbiol. Immun. 35:593.
